Core Insights - Solventum Corporation (SOLV) is a healthcare company with a market cap of $12.5 billion, focusing on solutions in separation and purification, health information, medical solutions, medical device components, and oral care [1] - The company is expected to announce its fiscal third-quarter earnings for 2025 on November 6, 2024 [1] Financial Performance - Analysts predict SOLV will report a profit of $1.42 per share for the upcoming quarter, reflecting a 23.5% increase from $1.15 per share in the same quarter last year [2] - For the full fiscal year, EPS is expected to be $5.94, down 11.3% from $6.70 in fiscal 2024, but is projected to rise 5.2% to $6.25 in fiscal 2026 [3] Stock Performance - SOLV stock has underperformed the S&P 500 Index, which gained 16.2% over the past 52 weeks, while SOLV shares have seen a marginal decline [4] - However, SOLV outperformed the Health Care Select Sector SPDR Fund, which dipped by 2.9% during the same period [4] Recent Developments - On August 7, SOLV reported Q2 results that exceeded expectations, with net sales increasing by 3.8% year over year to $2.2 billion, driven by growth in all business segments [5] - The adjusted EPS for Q2 reached $1.69, an 8.3% increase from the previous year, surpassing analyst estimates by 16.6% [5] - Following the Q2 results, the company raised its fiscal 2025 guidance, now expecting adjusted EPS between $5.80 and $5.95, along with organic sales growth of 2% to 3% [5] Analyst Sentiment - The consensus opinion on SOLV stock is moderately bullish, with a "Moderate Buy" rating from analysts [6] - Out of 15 analysts, five recommend a "Strong Buy," nine suggest a "Hold," and one advises a "Strong Sell" [6] - The average analyst price target for SOLV is $85.60, indicating a potential upside of 18.4% from current levels [6]